Announcements Trials
Browse Landscape

Phase

Phase 2 53Phase NA 9Phase 1 9Phase 1/2 6Phase 3 3Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Leukemia 3Congenital Abnormalities 3Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1TP53 1Sezary Syndrome 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Older Patients 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1

Interventions

Dexamethasone 8daratumumab 5Lenalidomide 5Bortezomib 5Thalidomide 4Cyclophosphamide 4carfilzomib 2Melphalan 2Calcium Dobesilate 2trametinib 1tanespimycin 1pomalidomide 1fludarabine 1dabrafenib 1cobimetinib 1Whole-Body Irradiation 1Vemurafenib 1Stem Cell Transplantation 1Rivaroxaban 1Mesna 1MAGEA3 protein, human 1Lenograstim 1Human Growth Hormone 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Busulfan 1Bone Marrow Transplantation 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Multiple Myeloma × Busulfan × Clear all
NCT03385096 2020-02-25

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
122 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡